As Obese, Overweight Population Grows in the U.S., More Treatment Options Are Needed

A study recently published in the Lancet paints a grim picture of the obesity epidemic in the United States: nearly three quarters of adults in the U.S. are classified as overweight or obese. The health risks associated with this are significant and include diabetes, high blood pressure, heart disease, and shortened lifespan.  

As a company developing an innovative weight loss drug, Endevica Bio is committed to addressing this pressing issue. We are researching a peptide that shows promising results in preclinical studies. Our research indicates that this experimental drug could be a more effective and well-tolerated option than current GLP-1 treatments.  

In a recent study, obese monkeys treated with our drug experienced a significant weight loss of 7.5% within one month, compared to a control group. This was accompanied by a 20% reduction in daily caloric intake, suggesting a powerful appetite-suppressing effect.  

While further research is needed, these early findings are encouraging and could represent a significant breakthrough in the fight against obesity. We fully agree with the conclusion of the Lancet study: “To protect population health, avoid overwhelming the health-care system, and mitigate mounting health-care costs, deliberate concerted action is needed to disrupt the epidemic of overweight and obesity.”  

We believe that our experimental drug, combined with other therapeutic interventions and lifestyle changes, could be a valuable tool in combating the growing obesity epidemic. By creating new options for the growing number of overweight Americans, we can help individuals achieve and maintain a healthy weight, ultimately improving their overall health and well-being.  

Russell Potterfield is the Chief Executive Officer of Endevica Bio.